Q3 2024 Earnings Call Transcript November 5, 2024 Apellis Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.46 EPS, expectations were $-0.32. Operator: Good morning, ladies ...

Apellis Pharmaceuticals, Inc. APLS incurred third-quarter 2024 loss of 46 cents per share, wider than the Zacks Consensus Estimate of a loss of 32 cents. The company had incurred a loss of $1.17 per ...

What’s an example of a well-executed drug launch? Look no further than Reata’s commercialization of Skyclarys, the first ...

Apellis Pharmaceuticals Inc (APLS) reports significant revenue growth but faces market and regulatory hurdles in Q3 2024.

Apellis Pharmaceuticals (APLS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

Apellis stock toppled Tuesday after third-quarter sales of the company's eye drug, Syfovre, widely missed Wall Street's expectations.Please watch the video at Investors.com - How To Buy Stocks: Ways ...

Apellis Pharmaceuticals (APLS) stock falls as company's Q3 2024 financials disappoint with lower-than-expected U.S. sales ...

Generated $196.8 million in 3Q 2024 revenues, including $176.6 million in U.S. net product salesGrew SYFOVRE® (pegcetacoplan injection) demand by ...

Although Syfovre has been approved for use in the ... $3.3 billion -- about 4.1 times its annualized second-quarter sales. Commercial-stage biotech stocks typically trade at mid-single-digit ...

Shares of Apellis Pharmaceuticals ( APLS 2.47%) are down by about 62% from the peak they reached in January. However, investment bank analysts who follow the drugmaker think its best days are still ...

The Citi analyst pointed out that despite the recent weak sentiment surrounding Apellis stocks, due to the European Union's non-approval of Syfovre and uncertainties regarding the strength of its U.S.